Bisphosphonates and MRONJ Risk in Dentistry

Drug group: Bisphosphonates

Examples: Alendronate, risedronate, ibandronate, pamidronate, zoledronic acid

German terms: Bisphosphonate, Antiresorptiva, Kiefernekrose, medikamentenassoziierte Kiefernekrose, MRONJ

Dental relevance: Risk assessment for medication-related osteonecrosis of the jaw before extractions, implants, periodontal surgery, dentoalveolar surgery, and poorly fitting dentures.

Key principle: Bisphosphonates should not be stopped by the dentist without medical coordination. The dental priority is prevention, risk stratification, atraumatic care, infection control, and clear follow-up.

This article is for dental education only. Bisphosphonate therapy may be prescribed for osteoporosis, Paget disease, multiple myeloma, or bone metastases. The medical indication strongly changes MRONJ risk. Do not advise a patient to stop bisphosphonate therapy without contacting the prescribing physician or specialist. Unplanned interruption may increase fracture or cancer-related skeletal risk and may not meaningfully reduce dental risk in many situations.

Bisphosphonates are antiresorptive drugs that reduce osteoclast-mediated bone resorption. They are useful for reducing fracture risk and managing cancer-related bone disease, but they are also associated with medication-related osteonecrosis of the jaw, or MRONJ.

MRONJ risk is not the same for every patient. A patient taking oral alendronate for osteoporosis usually has a much lower risk than a patient receiving high-dose intravenous zoledronic acid for metastatic cancer.

The key dental principle is: prevent avoidable dentoalveolar trauma by controlling infection early. Good dental prevention before and during antiresorptive therapy is safer than waiting until extraction becomes unavoidable.

• Best dental approach: identify risk early, optimize oral health, avoid preventable infection, and use conservative care when clinically reasonable.
• Main dental risk: delayed healing or exposed necrotic jaw bone after invasive dental procedures or trauma.
• Highest risk group: cancer patients receiving high-dose intravenous bisphosphonates or other high-dose antiresorptive/antiangiogenic therapy.
• Lower risk group: many osteoporosis patients receiving oral bisphosphonates, especially without additional risk factors.
• Clinical priority: know the drug, dose, indication, duration, route, comorbidities, and planned procedure risk.

Bisphosphonates bind strongly to mineralized bone. When osteoclasts resorb bone containing bisphosphonate, their function is reduced. This decreases bone turnover and can improve skeletal stability in osteoporosis or cancer-related bone disease.

• Therapeutic effect: reduced bone resorption and reduced skeletal complications.
• Dental concern: reduced bone remodeling can impair healing after jaw trauma or infection.
• Long persistence: many bisphosphonates remain in bone for a long time, especially after prolonged therapy.
• Jaw vulnerability: the jaws are exposed to teeth, plaque, periodontal infection, dentures, extractions, and frequent microtrauma.

Medication-related osteonecrosis of the jaw is a serious condition associated with antiresorptive or antiangiogenic drugs. A typical clinical picture includes exposed bone, or bone that can be probed through an intraoral or extraoral fistula, persisting for more than eight weeks in a patient with relevant medication exposure and no history of jaw radiation or metastatic disease to the jaws.

• Exposed yellow-white bone that does not heal
• Pain, swelling, infection, pus, or fistula in some cases
• Loose teeth, non-healing extraction socket, or sharp bone exposure
• Numbness, altered sensation, or sinus involvement in advanced cases
• May occur after extraction, denture trauma, periodontal infection, implants, or sometimes spontaneously

• Medication indication: cancer-related bone disease generally carries higher risk than osteoporosis treatment.
• Route and dose: high-dose intravenous therapy is higher risk than many oral osteoporosis regimens.
• Duration: longer treatment duration may increase risk.
• Procedure: extraction, implant placement, periodontal surgery, apical surgery, and bone surgery increase risk more than routine restorative care.
• Local disease: periodontitis, periapical infection, denture trauma, and poor oral hygiene increase risk.
• Systemic factors: corticosteroids, chemotherapy, diabetes, smoking, immunosuppression, and poor nutrition may increase risk.

• Ask the patient for the exact drug name, dose, route, indication, start date, and prescribing doctor.
• Identify whether the patient is treated for osteoporosis or malignant disease.
• Check for previous MRONJ, non-healing socket, jaw pain, exposed bone, or fistula.
• Prioritize prevention: periodontal therapy, caries control, denture adjustment, and oral hygiene.
• Prefer conservative dental treatment when it can predictably remove infection and preserve function.
• For invasive procedures, plan atraumatic technique, local infection control, careful closure when indicated, and close review.
• Refer or coordinate with oral surgery or specialist care for high-risk patients or complex surgery.
• Document informed consent, MRONJ discussion, risk factors, treatment alternatives, and follow-up.

• Current or previous MRONJ without specialist input
• High-dose IV bisphosphonate therapy for cancer with elective invasive procedure planned
• Non-urgent extraction where endodontic, periodontal, restorative, or palliative alternatives are reasonable
• Exposed bone, non-healing socket, unexplained jaw pain, fistula, or suspected MRONJ
• Uncontrolled infection or medical instability requiring medical coordination
• Implant planning in a high-risk patient without specialist risk assessment
• Patient does not understand MRONJ risk, alternatives, or follow-up requirements

A drug holiday means temporarily stopping antiresorptive therapy around dental surgery. For bisphosphonates, this is complex because many drugs remain bound in bone for years. Evidence is limited and recommendations vary according to risk group, medical indication, and specialist guidance.

• Do not decide alone: the dentist should not independently stop bisphosphonate therapy.
• Osteoporosis patients: many routine dental procedures can proceed with risk reduction rather than stopping medication.
• Cancer patients: specialist coordination is essential because skeletal complication risk is high.
• Practical focus: dental prevention, infection control, atraumatic technique, and follow-up are central regardless of drug holiday debate.

The biggest bisphosphonate mistake is discovering the medication only after an extraction fails to heal. Always ask about osteoporosis injections/tablets, cancer bone medications, antiresorptives, and “bone-strengthening” drugs before surgical dental treatment.

• Tell every dentist if you take or previously took bisphosphonates or other bone medications.
• Do not stop medication without speaking to your doctor.
• Keep excellent oral hygiene and attend regular dental check-ups.
• Report loose dentures, ulcers, sharp edges, exposed bone, non-healing sockets, pain, swelling, or pus.
• Seek early care for caries, gum disease, or broken teeth before extraction becomes unavoidable.
• If extraction is needed, the dentist may plan special precautions and closer follow-up.
• Smoking cessation and diabetes control can reduce oral healing risks.

In bisphosphonate patients, prevention is treatment. Every carious lesion, periodontal pocket, traumatic denture flange, and hopeless tooth should be managed early because delayed infection often forces higher-risk surgery later.

• Exposed bone that persists or a socket that does not heal
• Bone visible or probeable through a fistula
• Jaw pain, swelling, pus, or persistent infection
• Numbness, tingling, altered sensation, or “heavy jaw” feeling
• Loose teeth without clear periodontal explanation
• Denture ulceration over bony ridges that does not heal
• Pathologic fracture, sinus involvement, or extraoral fistula
• Patient receiving high-dose cancer-related antiresorptive therapy needing invasive dental care

• Denosumab
• Antiangiogenic cancer medications
• Medication-related osteonecrosis of the jaw
• Dental extraction risk assessment
• Implant planning in medically complex patients
• Denture trauma and ulcer prevention
• Periodontal infection control
• Dental clearance before oncology therapy

Bisphosphonates are antiresorptive medications used for osteoporosis and cancer-related bone disease. Their major dental relevance is medication-related osteonecrosis of the jaw, especially after extraction, implant surgery, periodontal surgery, denture trauma, or untreated oral infection. Risk depends strongly on indication, route, dose, duration, and comorbid factors. Oral osteoporosis therapy generally carries lower risk than high-dose intravenous cancer therapy. Dental management should focus on prevention, oral hygiene, periodontal and caries control, denture adjustment, risk assessment before invasive care, careful surgical technique, informed consent, and follow-up until healing. Dentists should not stop bisphosphonate therapy independently. Suspected MRONJ, high-risk oncology medication, non-healing sockets, exposed bone, fistula, infection, numbness, or planned complex surgery should trigger specialist coordination.